Quantcast
Viewing all articles
Browse latest Browse all 3448

Lilly, J&J both unveil positive late-stage data in Crohn's disease

Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also sharing long-term data in ulcerative colitis. In the Phase 3 GRAVITI study, J&J's subcutaneous Tremfya ...

Viewing all articles
Browse latest Browse all 3448

Trending Articles